A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.

News

A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.
The addition of daratumumab to a conventional regimen is associated with a 2-fold increase in PFS in patients with newly diagnosed multiple myeloma who are ineligible for transplant.
Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression.

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma, published in Supportive Care in Cancer (online November 7, 2017; doi:10.1007/s00520-017-3948-5).

Read More

Subscribe to Multiple Myeloma